From Germany: U.S. listed Immatics was founded in Tubingen and is based on foundational work on PRAME that was done here. A big pivotal is scheduled to read this year

20 hours ago
1 min read

Co-Founder & CEO Harpreet Singh walks us through the science of PRAME, which happened here at the University of Tubingen and led to the work the company does today. A cell therapy program in melanoma will have a pivotal read this year, and Immatics also has bispecific programs and a second generation cell therapy under development.

https://vimeo.com/1186992288

Recent Posts

See All

From Germany: HepaRegeniX hits a kinase that was discovered at the University of Tübingen to regenerate healthy liver cells when inhibited. They already have phase 1b data in hand from the Mayo Clinic

Unnatural Products has built its expertise in developing macrocyclic peptides. It had already landed four major partnerships before raising its series B in March

Replimune's Chairman discusses FDA's polarizing decision to not approve the company's melanoma treatment after a new review. He says they have filed a FOIA request to learn more about FDA's process

From Germany: U.S. listed Immatics was founded in Tubingen and is based on foundational work on PRAME that was done here. A big pivotal is scheduled to read this year

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight